CRISPR Therapeutics AG (CRSP.O)

+ 收藏

现金流量表(CRISPR Therapeutics AG)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年中报2024年一季报2023年年报2023年三季报2023年中报2023年一季报2022年年报2022年三季报2022年中报2022年一季报
起始日期 2024-01-012024-01-012023-01-012023-01-012023-01-012023-01-012022-01-012022-01-012022-01-012022-01-01
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表合并报表
报表年结日 1231123112311231123112311231123112311231
原始币种 美元美元美元美元美元美元美元美元美元美元
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后上市后上市后上市后
经营活动产生的现金流量:
 净利润(元) -242,999,000.00-116,591,000.00-153,610,000.00-242,957,000.00-130,805,000.00-53,065,000.00-650,175,000.00-539,600,000.00-365,051,000.00-179,217,000.00
 折旧及摊销(元) 9,678,000.004,833,000.0019,837,000.0014,937,000.0010,012,000.005,051,000.0024,172,000.0018,326,000.0013,308,000.006,039,000.00
 基于股票的补偿费(元) 43,077,000.0019,405,000.0081,028,000.0062,608,000.0042,640,000.0020,875,000.0097,947,000.0075,142,000.0050,597,000.0025,745,000.00
 经营业务调整其他项目(元) -16,566,000.00-8,385,000.00-14,045,000.00-9,279,000.00-4,120,000.00-969,000.0012,470,000.0012,251,000.009,671,000.006,099,000.00
 预付款项及其他应收款减少(增加)(元) 5,297,000.002,949,000.0023,219,000.0016,769,000.0015,952,000.0012,040,000.001,598,000.00---
 待摊费用及其他资产(元) -------7,062,000.002,032,000.004,611,000.00
 应收账款及票据减少(增加)(元) 200,000,000.00200,000,000.00-200,000,000.00--70,000,000.00-305,000.00256,000.00239,000.00162,000.00
 应付账款及票据增加(减少)(元) 18,724,000.009,443,000.00-20,247,000.00-11,056,000.0013,637,000.0025,214,000.005,164,000.0036,261,000.008,303,000.00-1,616,000.00
 递延收入(元) -775,000.00-504,000.005,794,000.007,000,000.00---1,011,000.00-762,000.00-1,011,000.00-762,000.00
 应计费用及其他负债(元) ---------1,148,000.00-154,000.00
 经营业务其他项目(元) -2,266,000.00-1,398,000.00-2,351,000.00-2,324,000.00-1,762,000.00-347,000.0013,789,000.008,651,000.005,865,000.003,854,000.00
 经营活动产生的现金流量净额(元) 14,170,000.00109,752,000.00-260,375,000.00-164,302,000.00-124,446,000.008,799,000.00-495,741,000.00-382,413,000.00-277,195,000.00-135,239,000.00
投资活动产生的现金流量:
 购买固定资产支付的现金(元) -1,428,000.00-721,000.00-9,470,000.00-8,732,000.00-6,614,000.00-3,059,000.00-37,188,000.00-30,997,000.00-24,980,000.00-15,350,000.00
 购买无形资产及其他资产支付的现金(元) ---------597,136,000.00-323,140,000.00
 处置无形资产及其他资产收到的现金(元) --------451,529,000.00223,975,000.00
 投资支付现金(元) -797,509,000.00-326,915,000.00-1,065,911,000.00-697,762,000.00-452,363,000.00-265,627,000.00-1,417,800,000.00-923,404,000.00--
 投资业务其他项目(元) 574,232,000.00229,836,000.001,450,028,000.001,162,594,000.00793,729,000.00386,515,000.001,196,333,000.00871,278,000.00--
 投资活动产生的现金流量净额(元) -224,705,000.00-97,800,000.00374,647,000.00456,100,000.00334,752,000.00117,829,000.00-258,655,000.00-83,123,000.00-170,587,000.00-114,515,000.00
融资活动产生的现金流量:
 发行股份(元) 279,733,000.00280,745,000.0032,721,000.00---970,000.00970,000.00--
 行使股票期权所得(元) 25,735,000.0025,189,000.0029,943,000.0023,725,000.0022,169,000.005,404,000.0037,622,000.0035,144,000.00--
 筹资业务其他项目(元) --------21,002,000.0010,649,000.00
 融资活动产生的现金流量净额(元) 305,468,000.00305,934,000.0062,664,000.0023,725,000.0022,169,000.005,404,000.0038,592,000.0036,114,000.0021,002,000.0010,649,000.00
汇率变动影响(元) -9,000.00-11,000.0073,000.0012,000.0060,000.0032,000.00-80,000.00-195,000.00-95,000.00-27,000.00
现金及现金等价物期初余额(元) 401,068,000.00401,068,000.00224,060,000.00224,060,000.00224,060,000.00224,060,000.00939,944,000.00939,944,000.00939,944,000.00939,944,000.00
现金及现金等价物增加(减少)额(元) 94,924,000.00317,875,000.00177,009,000.00315,535,000.00232,535,000.00132,064,000.00-715,884,000.00-429,617,000.00-426,875,000.00-239,132,000.00
现金及现金等价物期末余额(元) 495,992,000.00718,943,000.00401,068,000.00539,595,000.00456,595,000.00356,124,000.00224,060,000.00510,327,000.00513,069,000.00700,812,000.00
补充资料其他项目(元) 3,049,000.004,653,000.001,142,000.00763,000.001,322,000.00715,066,000.002,220,000.0024,470,000.00--
非现金活动(元) --------24,509,000.0019,120,000.00
公告日期 2024-08-052024-05-082024-02-212023-11-062023-08-072023-05-082023-02-212022-11-012022-08-082022-05-09
会计准则 美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则美国会计准则
审计意见
核数师

前瞻产业研究院